Title |
Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
|
---|---|
Published in |
Vascular Health and Risk Management, July 2013
|
DOI | 10.2147/vhrm.s34421 |
Pubmed ID | |
Authors |
Cong Zou, Honglin Hu |
Abstract |
Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk- benefit analysis to determine what role pioglitazone should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed. This review provides a comprehensive overview of the present literature. Clinical data currently available indicate that pioglitazone is an effective and generally well-tolerated treatment option for use in patients with type 2 diabetes. Pioglitazone can still reduce adverse cardiovascular risk. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 20% |
Student > Bachelor | 3 | 12% |
Researcher | 3 | 12% |
Student > Ph. D. Student | 2 | 8% |
Lecturer | 2 | 8% |
Other | 2 | 8% |
Unknown | 8 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 40% |
Agricultural and Biological Sciences | 2 | 8% |
Nursing and Health Professions | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Engineering | 1 | 4% |
Other | 0 | 0% |
Unknown | 10 | 40% |